Previous close | 28.66 |
Open | 28.58 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 28.58 - 28.95 |
52-week range | 20.75 - 41.86 |
Volume | |
Avg. volume | 1,779 |
Market cap | 28.408M |
Beta (5Y monthly) | 0.72 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.08 |
Earnings date | 30 Apr 2024 - 06 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
PASADENA, Calif., March 25, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has initiated an Expanded Access Program (EAP) to make investigational plozasiran available outside of a clinical trial for patients with familial chylomicronemia syndrome (FCS) who meet certain program eligibility criteria. Arrowhead will also present new final Phase 2 clinical data from the double-blind portion of the SHASTA-2 study of plozasiran in a late-breaking oral presentation at the
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) CFO Kenneth Myszkowski sold 40,000 shares of the company's stock on March 6, 2024, according to a recent SEC filing.
PASADENA, Calif., March 08, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a double-blinded, placebo-controlled, dose-escalating study (NCT06138743) to evaluate single and multiple ascending doses of ARO-DM1, the company’s investigational RNA interference (RNAi) therapeutic, in up to 48 subjects with type 1 myotonic dystrophy (DM1). DM1 is the most common adult-onset muscular dystrophy.